Central Drugs Lab: 55 Drug Samples Fail Quality Tests in June 2025

Описание: 00:00 - Intro
00:21 - Central Drugs Lab: 55 Drug Samples Fail Quality Tests in June 2025
04:19 - 55 Drug Samples Found to be 'Not of Standard Quality' in June
07:07 - Top Drug Regulator Flags 185 Substandard, 4 Spurious Drugs in June 2025

1. Central Drugs Lab: 55 Drug Samples Fail Quality Tests in June 2025

Central Drugs Laboratories June 2025 Report: 55 Drug Samples Fail Quality Standards | CDSCO Update

In this video, we dive into the latest report from the Central Drugs Standard Control Organisation (CDSCO) revealing how 55 drug samples were flagged as "not of standard quality" in June 2025. State testing labs also identified 130 substandard samples, while spurious drugs were detected in Bihar, Delhi, and Telangana.

Key points:
What “not of standard quality” means and which parameters were tested
Details on spurious drugs manufactured by unauthorized entities
How CDSCO and state regulators collaborate on drug surveillance
Impact on patient safety and steps taken to remove bad batches

Stay informed about pharmaceutical quality and healthcare regulation in India. Subscribe for regular updates on drug safety, policy changes, and industry news!

2. 55 Drug Samples Found to be 'Not of Standard Quality' in June

The Central Drugs Laboratories have identified 55 drug samples manufactured by various firms in June to be 'not of standard quality'.
State drugs testing laboratories have also identified 130 drugs samples as 'not of standard quality'.
The identification of 'not of standard quality' and spurious medicines is done on a regular basis in collaboration with state regulators to ensure that these drugs are identified and removed from the market.
Watch this video to know more about the details of the report and the actions being taken by the authorities.

3. Top Drug Regulator Flags 185 Substandard, 4 Spurious Drugs in June 2025

The Central Drugs Standard Control Organisation (CDSCO) and state drugs testing laboratories identified 185 drug samples as 'Not of Standard Quality' (NSQ) and four as 'spurious' during routine regulatory surveillance in June. The Union health ministry said that these drug samples failed one or more specified quality parameters, ranging from inadequate active ingredients to issues with dissolution, uniformity of weight, or sterility. Investigations revealed that these spurious drugs were manufactured by unauthorized entities using brand names owned by legitimate companies, highlighting the severity of the counterfeit drug problem. The government has implemented several measures to combat the menace of spurious and substandard drugs in India.